SNCA and Parkinson disease: The recent high interest in the reduction of α-synuclein level as a therapeutic approach to prevent PD progression makes it more than ever important to obtain strong experimental evidence that α-synuclein loss-of-function induced in neurons of the adult or aging nigrostriatal system does not cause adverse effects in the long term.